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Arsenic intoxication is a worldwide problem.
Billions of people in India, Bangladesh, Inner
Mongolia, Taiwan, and North and South
America have drunk arsenic-contaminated
water for many years (National Research
Council 1999) and suffer from a variety of
arsenic-induced diseases, such as cancer, dia-
betes, hypertension, and hyperkeratosis
(Chen et al. 1992; Haque et al. 2003; Liu
et al. 2002). During the past few decades,
arsenic carcinogenesis has been extensively
studied using a variety of in vitro molecular
cytogenetic approaches and in vivo animal
models (Chen et al. 2004; Kitchin 2001;
Rossman 2003; Waalkes et al. 2004). The
carcinogenesis-associated effects of arsenic
involve genotoxic damage such as chromo-
somal abnormalities and oxidative stress
(Basu et al. 2001; Hei and Filipic 2004;
Rossman 2003). In addition to genetic altera-
tions, arsenic exposure was  shown recently to
induce both global hypomethylation (Xie
et al. 2004) or specific hypomethylation of
the cyclin D1 and estrogen receptor-α genes
(Chen et al. 2004) and hypermethylation of
the p53 (tumor suppressor protein p53) gene
(Mass and Wang 1997). Epigenetic alter-
ations caused by modification of DNA
methylation are therefore considered to play
crucial roles in arsenic carcinogenesis
(Sutherland and Costa 2003).
Microarray technology, which measures
changes in gene expression at the transcrip-
tional level, is a powerful tool for studying
global cellular responses to toxicants (Waters
and Fostel 2004). Numerous reports have
demonstrated that genes showing aberrant
expression after exposure to inorganic trivalent
arsenic are involved in signal transduction, cell
proliferation, oxidative stress responses, and
DNA repair in a variety of cell systems (Bae
et al. 2003; Chen et al. 2001a; Hamadeh et al.
2002; Rea et al. 2003; Yih et al. 2002; Zheng
et al. 2003) as well as in liver tumors in mice
(Chen et al. 2004; Liu et al. 2004). We
recently examined gene expression proﬁles in
lymphocytes from an arsenic-exposed human
population and found that the expression of
several inflammatory molecules is increased
after prolonged exposure to arsenic (Wu et al.
2003). Furthermore, we and others have
shown that long-term exposure to low concen-
trations of arsenic causes increased neoplastic
transformation of a variety of cells (Achanzar
et al. 2002; Chien et al. 2004; Mure et al.
2003; Zhao et al. 1997). These studies
strongly suggest that chronic exposure to low
levels of arsenic results in epigenetic alterations
that may promote arsenic-induced neoplastic
transformation or tumor development.
Ingested inorganic arsenic compounds are
metabolized by oxidative methylation (Kitchin
2001; Styblo et al. 2002; Thomas et al. 2001).
Inorganic pentavalent arsenate (iAsV), trivalent
arsenite (iAsIII), and the intermediate metabo-
lites of monomethylarsonic acid (MMAV),
monomethylarsonous acid (MMAIII), dimethy-
larsinic acid (DMAV), and dimethylarsinous
acid (DMAIII) have been identiﬁed in the urine
of arsenic-exposed subjects (Mandal et al. 2004;
Wang et al. 2004). MMAV and DMAV are
nontoxic, but MMAIII and DMAIII are more
toxic than iAsIII for a variety of cell lines (Styblo
et al. 2000; Thomas et al. 2001; Vega et al.
2001). MMAIII and DMAIII are genotoxic for
human lymphocytes (Kligerman et al. 2003)
and Chinese hamster ovary cells (Dopp et al.
2004) and may interfere with DNA repair to a
greater extent than MMAV and DMAV
(Schwerdtle et al. 2003). The realization that
MMAIII and DMAIII also cause injury has led
to a better understanding of arsenic-mediated
carcinogenesis, but their roles in arsenic
carcinogenesis remain to be clariﬁed.
To explore the effects of long-term expo-
sure of human urothelial cells to iAsIII and its
toxic trivalent metabolites, MMAIII and
DMAIII, we initiated a systematic study of gene
expression changes using cDNA microarray in
an SV40-immortalized human urethra–derived
urothelial cell line, SV-HUC-1 (HUC-1)
(Christian et al. 1987). An HUC-1–derived
3-methylcholanthrene–induced tumorigenic
cell line, MC-SV-HUC T2 (MC-T2)
(Reznikoff et al. 1988) was also included to
examine the relationship between the changes
caused by arsenic exposure and tumorigenicity.
In this report, we show that chronic exposure
to trivalent arsenicals induced compound-
specific cell morphologic changes. Different
gene expression profiles were produced by
exposure to these three trivalent arsenicals, and
that caused by iAsIII most closely resembled the
proﬁle seen in MC-T2 cells. A reduction in the
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Inorganic arsenic is an environmental carcinogen. The generation of toxic trivalent methylated
metabolites complicates the study of arsenic-mediated carcinogenesis. This study systematically evalu-
ated the effect of chronic treatment with sodium arsenite (iAsIII), monomethylarsonous acid
(MMAIII), and dimethylarsinous acid (DMAIII) on immortalized human uroepithelial cells
(SV-HUC-1 cells) using cDNA microarray. After exposure for 25 passages to iAsIII (0.5 µM), MMAIII
(0.05, 0.1, or 0.2 µM), or DMAIII (0.2 or 0.5 µM), significant compound-specific morphologic
changes were observed. A set of 114 genes (5.7% of the examined genes) was differentially expressed
in one or more sets of arsenical-treated cells compared with untreated controls. Expression analysis
showed that exposure of cells to DMAIII resulted in a gene proﬁle different from that in cells exposed
to iAsIII or MMAIII, and that the iAsIII-induced gene proﬁle was closest to that in the tumorigenic
HUC-1–derived 3-methylcholanthrene–induced tumorigenic cell line MC-SV-HUC T2, which was
derived from SV-HUC-1 cells by methylcholanthrene treatment. Of the genes affected by all three
arsenicals, only one, that coding for interleukin-1 receptor, type II, showed enhanced expression, a
ﬁnding conﬁrmed by the reduced increase in NF-κB (nuclear factor kappa B) activity seen in response
to interleukin-1β in iAsIII-exposed cells. The expression of 11 genes was suppressed by all three arseni-
cals. 5-Aza-deoxycytidine partially restored the transcription of several suppressed genes, showing that
epigenetic DNA methylation was probably involved in arsenical-induced gene repression. Our data
demonstrate that chronic exposure to iAsIII, MMAIII, or DMAIII has different epigenetic effects on
urothelial cells and represses NF-κB activity. Key words: cDNA microarray, immortalized urothelial
cells, real-time polymerase chain reaction, toxicogenomics, trivalent arsenite, trivalent methylated
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increase in NF-κB (nuclear factor kappa B)
activity in response to interleukin 1β (IL1B)
treatment was seen in arsenical-exposed cells.
5-Aza-deoxycytidine (5-aza-dC) restoration
experiments showed that DNA hypermethyla-
tion was involved in the changes in gene
expression caused by exposure to trivalent
arsenicals.
Materials and Methods
Cell culture and arsenic compounds. HUC-1
cells (CRL-9520) and MC-T2 cells (CRL-
9519) were purchased from American Type
Culture Collection (Manassas, VA, USA) and
grown in F-12 nutrient mixture (Ham)
medium (Gibco Invitrogen Life Technologies,
Carlsbad, CA, USA) supplemented with 10%
fetal calf serum (Hyclone Laboratory, Logan,
UT, USA), 2 mM L-glutamine, 100 U/mL of
penicillin, and 100 µg/mL streptomycin sulfate
at 37°C in a humidiﬁed atmosphere contain-
ing 5% CO2. Both lines were shown to be
mycoplasma-free by polymerase chain reaction
(PCR) analysis. In nude mice, HUC-1 cells are
nontumorigenic, whereas MC-T2 cells form
tumors. iAsIII (sodium arsenite, Art. 6287) was
purchased from Merck KGaA (Darmstadt,
Germany). MMAIII and DMAIII were synthe-
sized in our laboratory, and their chemical
structure and purity were veriﬁed by nuclear
magnetic resonance, mass spectrophotometry,
and element analysis.
Cytotoxicity assay and long-term exposure
to iAsIII, MMAIII, or DMAIII. The cytotoxicity
of the three trivalent arsenic compounds for
HUC-1 cells was determined using the sulfo-
rhodamine B (SRB) colorimetric assay (Skehan
et al. 1990). Brieﬂy, 1 × 104 cells in 0.1 mL of
F12 medium were seeded in each well of a
96-well plate and incubated for 72 hr with var-
ious concentrations of iAsIII, MMAIII, or
DMAIII. The cells were then ﬁxed with 50%
trichloroacetic acid, stained for 30 min at room
temperature with 0.4% SRB in 10% acetic
acid, and extracted for 5 min at room tempera-
ture with unbuffered 10 mM Tris-base solu-
tion, and the absorbance of the extract was
measured at 540 nm. The growth-inhibiting
and cytotoxic effects of the arsenicals were
calculated using the formula [(Atreated – Azero)/
(Acontrol – Azero)] × 100%, where Azero is the
absorbance at the time of drug addition and
Acontrol and Atreated are the absorbance of
untreated and treated wells, respectively, at the
end of the experiment. IC50 (median
inhibitory concentration) values were calcu-
lated using CalcuSyn software (Biosoft,
Cambridge, UK).
To establish arsenic long-term exposed cell
lines, we maintained HUC-1 cells in the pres-
ence of trivalent arsenicals at doses giving a
90% cell survival rate, namely, 0.5 µM iAsIII,
0.2 or 0.5 µM DMAIII, or 0.05, 0.1, or 0.2 µM
MMAIII. The trivalent arsenical-treated and
untreated HUC-1 cells were subcultured twice
weekly for at least 20–25 passages before being
subjected to microarray assay.
Preparation of total and poly(A)+ RNA.
Total cellular RNA was extracted using TRI
reagent (Molecular Research Center,
Cincinnati, OH, USA) according to the
manufacturer’s instructions. Poly(A)+ RNA
was then isolated using an Oligotex mRNA
midi kit (Qiagen, Hilden, Germany).
cDNA microarray analysis. The micro-
array chips were made in-house from a collec-
tion of approximately 2,000 expressed gene
sequences, including genes of potential signiﬁ-
cance in arsenic toxicity (Wu et al. 2003) and
genes selected from subtraction libraries estab-
lished from oral carcinoma, nasopharyngeal
carcinoma, colon cancer, and hepatoma (pro-
vided by K.W. Chang, National Yang-Ming
University); detailed information on these
genes is available from the Institute of
Biomedical Sciences, Academia Sinica (Taipei,
Taiwan; http://www.ibms.sinica.edu.tw/
~bmtcl/As-chip-TCL04.xls). Sources of gene
information are GenBank (http://www.ncbi.
nih.gov/genbank/) and CGAP (Cancer
Genome Anatomy Project; http://cgap.nci.nih.
gov/Genes). The cDNA microarray hybridiza-
tion experiments were performed using a col-
orimetric detection method as described
previously (Wu et al. 2003; Yih et al. 2002).
Brieﬂy, cDNA targets were prepared from 2 µg
of mRNA using Superscript II reverse tran-
scriptase (Gibco Invitrogen Life Technologies)
by incorporating biotin-16-2´-deoxyuridine-
5´-triphosphate (Roche Diagnostics,
Mannheim, Germany). The labeled cDNA
targets were hybridized to the membrane array
overnight at 65°C, then the arrays were washed
and incubated for 60 min at room temperature
with streptavidin-conjugated alkaline phos-
phatase for chromagen development. After
extensive washes to remove any unbound con-
jugate, substrate solution (0.1 M Tris, pH 9.5,
0.1 M NaCl, 5 mM MgCl2, 165 µg/mL nitro-
tetrazolium blue chloride, and 87 µg/mL
bromo-4-chloro-3-indolyl phosphate p-tolui-
dine salt) was added to the array, which was
then incubated in the dark at room tempera-
ture for 15–20 min with occasional shaking.
The intensity of the spots on the arrays was
measured using a scanner at an appropriate
optical resolution. Quantitative results were
obtained using GenePix (version 4.0; Axon
Instruments, Union, CA, USA), normalized by
a linear regression method, then analyzed and
clustered using Spotfire (Spotfire Inc.,
Somerville, MA, USA). For each treatment,
the microarray analysis was repeated 4 times.
Quantitative real-time reverse-transcriptase
PCR. We used total RNA as the template in
the synthesis of first-strand cDNA using an
oligo(dT) primer and the AMV reverse tran-
scriptase system (Roche Diagnostics). The PCR
primers used to detect the genes of interest and
the internal control gene, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), are
listed in Table 1. Quantitative real-time
RT-PCR (Q-PCR) was performed using an
ABI PRISM 7700 sequence detection system
(Applied Biosystems, Foster City, CA, USA).
Thermocycling was performed in a ﬁnal vol-
ume of 10 µL containing 4 µL of cDNA sam-
ple, 200 nM of each of the primers, and 5 µL of
SYBR green PCR master mix (Applied
Biosystems). The relative differences in expres-
sion level between genes were expressed using
cycle time (Ct) values as follows: the Ct value of
the gene of interest was ﬁrst normalized to that
for GAPDH in the same sample, then the dif-
ference between the treatment and control
group was calculated and expressed as an
increase or decrease in cycle numbers compared
with the control.
Semiquantitative RT-PCR and agarose
gel electrophoresis. Total RNA was isolated
and converted into first-strand cDNA as
described above. The cDNA for the test gene
was amplified by PCR using the Ampli Taq
gold system (Applied Biosystems). The PCR
conditions were 94°C for 10 min; 35 cycles of
94°C for 30 sec, 55°C for 30 sec, and 72°C
Table 1. Primer sequences used for Q-PCR and RT-PCR.a
Gene Forward primer Reverse primer
CDH1 AACGCATTGCCACATACACTCT CATTCTGATCGGTTACCGTGATC
E2F1 GAGCAGATGGTTATGGTGATCAAA AGGGCACAGGAAAACATCGA
GAPDH GGAGTCCCTGCCACACTCA GCCCCTCCCCTCTTCAAG
GJA1 CCAAAGACTGTGGGTCTCAA CTCACTTGCTTGCTTGTTGTA
HBEGF AGGACTTCTGCATCCATGGA TGGTCATAGGTATATAAGCGAT
IGFBP5 CTCACTTGCTTGCTTGTTGTA GCACTGCTTTCTCTTGTAGAA
IL1R2 TGTGCTGGCCCCACTTTC GCACAGTCAGACCATCTGCTTT
IL8 GTGCAGTTTTGCCAAGGA TTCTGTGTTGGCGCAGTG
KRT13 GCGGGACTACAGCCCCTACTAC CCAGCCTGGCATTGTCAAT
MMP2 GCACTGCTTTCTCTTGTAGAA GATCTGAGCGATGCCATCAA
PRSS11 CCGTGGTTCATATCGAATTGT CCGTGGTTCATATCGAATTGT
S100A8 TGGAGAAAGCCTTGAACTCTATCA GGTCTCTAGCAATTTCTTCAGGTCAT
THBD GAGGACGTGGATGACTGCATACT GGTACTCGCAGTTGGCTCTGA
VAV3 GAACAAGGGACACTCAAACTACCA GTTCCTAATGACCTGCATCTTTGG
aPrimer sequences were designed by Primer Express 2.0 (Applied Biosystems) according to their sequence ID shown in
Supplementary Material, Table 1 (http://ehp.niehs.nih.gov/members/2005/8174/suppl.pdf).for 30 sec; and 72°C for 7 min. The PCR
products were analyzed on a 1.5% agarose gel.
GAPDH RNA levels were analyzed in parallel
to ensure that equal amounts of cDNA were
loaded for each reaction
Immunoblotting analysis. Cells were har-
vested in ice-cold phosphate-buffered saline,
pH 7.4, using a rubber policemen, then lysed
by addition of an equal volume of 2× sodium
dodecyl sulfate (SDS) lysis buffer (100 mM
Tris HCl, pH 6.8, 200 mM β-mercapto-
ethanol, 4% SDS, 0.2% bromophenol blue,
and 20% glycerol). The protein concentration
was determined using a Bio-Rad Protein Assay
system (Bio-Rad Laboratory, Hercules, CA,
USA) with bovine serum albumin as standard.
Equal amounts (20 µg of protein) of each sam-
ple were electrophoretically separated on a
10% SDS polyacrylamide gel and electro-
transferred to a PVDF (polyvinylidene diﬂuo-
ride) membrane. After blocking with 4% skim
milk, the membranes were probed with pri-
mary mouse antibodies against heparin-binding
epidermal growth factor-like growth factor
(AF-259-NA; R&D System, Inc., Minneapolis,
MN, USA), E-cadherin (sc-8426) or keratin
10/13 (sc-6258) (both from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), or
integrin β3 (611141; BD Transduction
Laboratories, Franklin Lakes, NJ, USA) or goat
antibody against β-actin (sc-1616; Santa Cruz
Biotechnology, Inc.), followed by secondary
horseradish peroxidase–conjugated antibodies
against goat or mouse IgG (AP106P or
AP124P; Chemicon International Inc.,
Temecula, CA, USA). Bound antibody was
visualized using enhanced SuperSignal West
Pico chemiluminescent substrate (Pierce
Biotechnology, Inc., Rockford, IL, USA).
β-Actin was used as the loading control.
Transfection and NF-κB activity assay. To
measure NF-κB activity, we used the
pNF-κB-Luc reporter (Stratagene, La Jolla,
CA, USA) containing five NF-κB enhancer
motifs and the coding sequence for firefly
luciferase. The pRL-TK plasmid containing
Renilla luciferase driven by thymidine kinase
promoter (Promega Corp., Madison, WI,
USA) was used as the internal control. Cells
were seeded at 1.5 × 105 per well in 24-well
plates the day before and transfected with
0.25 µg of pNF-κB-Luc reporter and 0.05 µg
pRL-TK with 0.9 µL FuGene 6 reagent
(Roche Diagnostics) following the manufac-
turer’s instructions. The cells were incubated
in the presence of serum-containing medium
for 16 hr followed by serum starvation for
24 hr. Human recombinant IL1B (201-LB,
R&D System, Inc.) was added as indicated
concentrations, and incubation continued for
5 hr. The cells were then harvested, and ﬁreﬂy
and Renilla luciferase activities were measured
using the Dual-Luciferase assay system
(E1910, Promega Corp.) according to the
manufacturer’s protocol. The NF-κB activity
associated with the ﬁreﬂy activity was normal-
ized to the Renilla luciferase activity.
5-Aza-dC treatment. HUC-1 cells exposed
to 0.2 µM MMAIII for 25 passages were incu-
bated for 72 hr with 0, 0.5, or 2.0 µM
5-aza-dC (A3656, Sigma-Aldrich Co.).
Passage-matched HUC-1 cells not treated with
MMAIII or 5-aza-dC were used as controls.
The expression level of the test gene in the con-
trol HUC-1 cells was taken as 100%.
Results
Morphologic changes induced in HUC-1
cells by long-term exposure to iAsIII, MMAIII,
or DMAIII. To establish an in vitro culture sys-
tem for studying the chronic effect of arsenicals
on urothelial cells, we determined the toxicity
of three trivalent arsenicals iAsIII, MMAIII, and
DMAIII for nontumorigenic HUC-1 cells
using the SRB colorimetric assay (Figure 1)
and found the IC50 values to be 2.91 ± 0.58,
0.46 ± 0.11, and 1.59 ± 0.26 µM, respectively.
For long-term treatment, HUC-1 cells were
continuously grown in the presence of trivalent
Su et al.
396 VOLUME 114 | NUMBER 3 | March 2006 • Environmental Health Perspectives
Figure 1. Cytotoxicity of iAsIII, MMAIII, and DMAIII
for HUC-1 cells. HUC-1 cells (1 × 104 cells/well)
were seeded in a 96-well plate and exposed for
3 days to various concentrations of iAsIII, MMAIII, or
DMAIII; surviving cells were then estimated using
the SRB colorimetric assay. The data are the mean
± SD for at least three independent experiments.
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Figure 2. Photomicrographs of HUC-1 cells after long-term exposure to different arsenicals. The morphol-
ogy of HUC-1 cells left untreated or incubated with 0.2 µM MMAIII (M 0.2), 0.2 or 0.5 µM DMAIII (D 0.2,
D 0.5), or 0.5 µM iAsIII (iAs 0.5) for 23–25 passages was examined under a phase-contrast microscope.
Tumorigenic MC-T2 cells were included as controls. Bars = 100 µm.arsenicals at a dose lower than that giving 90%
cell survival, that is, 0.05, 0.1, or 0.2 µM
MMAIII; 0.2 or 0.5 µM DMAIII; and 0.5 µM
iAsIII. Control HUC-1 cells were processed in
parallel without arsenicals.
After in vitro maintenance for 25 passages,
the morphology of the untreated HUC-1 cells
was unchanged, but long-term exposure to
arsenicals resulted in significant changes.
HUC-1 cells exposed to iAsIII or MMAIII
tended to aggregate, were smaller in size than
untreated cells (Figure 2), and required longer
trypsin digestion to detach them from the
surface (data not shown), indicating increased
adhesion activity. Long-term exposure to
DMAIII induced morphologic changes in a
concentration-dependent manner, and these
differed from those induced by iAsIII and
MMAII; DMAIII did not induce signiﬁcant cell
aggregation, but the size of the cells was
reduced by exposure to 0.2 µM DMAIII, and
this effect was greater using 0.5 µM DMAIII.
These results show that chronic exposure to
trivalent arsenic compounds induced differen-
tial morphologic changes in urothelial cells and
that none of the induced morphologies resem-
bled that of tumorigenic MC-T2 cells. The
proliferation activity of cells cultured in the
presence of each arsenical was 70–80% that of
untreated controls except for cells exposed to
0.5 µM DMAIII for which the proliferation
rate was 40–50% that of untreated controls.
The tumorigenicity assay showed that HUC-1
cells exposed long term to these trivalent
arsenicals were still nontumorigenic in nude
mice after subcutaneous injection of 5 × 106
cells, which is in contrast to the results of our
previous study (Chien et al. 2004) showing
that HaCaT cells (immortalized but non-
tumorigenic human keratinocytes) become
tumorigenic in nude mice after long-term
exposure to low-dose iAsIII.
Induction of different gene profiles in
HUC-1 cells after long-term exposure to iAsIII,
MMAIII, or DMAIII. To evaluate global
changes in gene expression induced by long-
term exposure to low-dose iAsIII, MMAIII, or
DMAIII, we used a colorimetric cDNA array
(Wu et al. 2003; Yih et al. 2002). We used
passage-matched untreated HUC-1 cells as the
negative control, and included tumorigenic
MC-T2 cells to examine the relationship
between changes induced by arsenic exposure
and tumorigenesis. As shown in Figure 3A,
the intensity (arbitrary units) of the signal for
the internal control gene GAPDH was similar
in untreated and arsenical-treated cells (p =
0.3008 by analysis of variance), and similar
results were obtained for two other commonly
used human housekeeping genes, the trans-
ferrin receptor (p90, CD71) (TFRC) and
hypoxanthine phosphoribosyltransferase 1
(HPRT1), except that TFRC levels in iAsIII-
treated HUC-1 cells were slightly, but signiﬁ-
cantly, lower than those in untreated HUC-1
cells. These results showed that the intraassay
variation was acceptable.
We selected a set of 114 differentially
expressed genes (5.7% of the tested genes)
(Supplementary Material, Table 1; http://
ehp.niehs.nih.gov/members/2005/8174/
suppl.pdf) on the basis of the criteria that there
was a signiﬁcant difference (p < 0.05, Student’s
t-test, n = 4) between the expression of the
gene in untreated HUC-1 cells and in treated
HUC-1 cells and/or MC-T2 cells, and that the
ratio for the expression in one or more sets of
treated HUC-1 cells and/or MC-T2 cells com-
pared with the expression in untreated HUC-1
cells was > 1.9 or < 0.25. A hierarchical den-
drogram of the 114 selected genes is shown in
Figure 3B. The expression profiles in cells
exposed to different concentrations of MMAIII
or DMAIII were clearly clustered as separate
groups. The gene expression pattern most
closely resembling that in MC-T2 cells was
seen in the iAsIII-exposed HUC-1 cells. The
profile of down-regulated genes in HUC-1
cells exposed to MMAIII, especially at 0.2 µM,
also shared similarities with the MC-T2 cell
proﬁle. DMAIII-treated HUC-1 cells showed a
profile distinct from those in the other cells.
Together, these gene expression proﬁles show
that these three different trivalent arsenic com-
pounds had different effects on the cells.
To characterize the trivalent arsenical-
responsive genes, the selected 114 genes were
subjected to Gene Ontology–based biologic
property analysis (FatiGO; http://www.fatigo.
org/) (Al-Shahrour et al. 2004). Ninety-eight
genes of known annotation were submitted, of
which 85 were acceptable for level 3 biologic
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Figure 3. Analysis of changes in gene expression induced by trivalent arsenicals. Abbreviations: D, DMAIII; M,
MMAIII. (A) Intraslide expression levels for the internal control genes, glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), transferrin receptor (TFRC), and hypoxanthine phosphoribosyltransferase 1 (HPRT1).
(B) Hierarchical dendrogram of the gene expression changes. A set of 114 genes showing differential expres-
sion in one or more of the arsenical-treated cell lines or MC-T2 cells compared with untreated HUC-1 cells
was subjected to hierarchical clustering using the Spotﬁre clustering program. Increased mRNA levels are
shown as shades of red, and decreased levels as shades of green. Names of genes are listed in
Supplementary Material, Table 1 (http://ehp.niehs.nih.gov/members/2005/8174/suppl.pdf). (C) Gene Ontology-
based analysis.process analysis (Figure 3C). The major gene
population (80%) was categorized as “cellular
physiologic processes” covering the processes
of cell growth and maintenance, cell death,
mobility, and transport. In addition, 61.8% of
the genes were associated with metabolism
(metabolism of nucleic acids, proteins, fatty
acids, and vitamin B6; protein phosphoryla-
tion and targeting; RNA processing; ubiqui-
tin-dependent proteolysis; and regulation of
transcription), 36.5% with cell communica-
tion (cell adhesion, cell–cell signaling, and sig-
nal transduction), 25.9% with responses to
stimuli (endogenous and exogenous), and
23.5% with morphogenesis (cellular morpho-
genesis and organogenesis).
Confirmation of gene expression profiles 
by Q-PCR and immunoblotting assays. The
arsenical-induced changes in gene expres-
sion identified by microarray analysis
(Supplementary Material, Table 1; http://
ehp.niehs.nih.gov/members/2005/8174/
suppl.pdf) were checked by Q-PCR. Thirteen
of the 114 genes were tested. These 13 included
2 genes [S100 calcium binding protein A8
(S100A8) and E-cadherin (CDH1)] showing
no change or enhanced expression in all sets of
arsenical-treated HUC-1 cells in the microarray
assay, 4 genes [connexin 43 (GJA1), matrix
metalloproteinase type 2 (MMP2), protease,
serine 11 (IGF binding) (PRSS11), and insulin-
like growth factor binding protein 5 (IGFBP5)]
showing decreased expression in all sets of
arsenical-treated HUC-1 cells, and 7 genes
[thrombomodulin (THBD), interleukin-8
(IL8), heparin-binding epidermal growth fac-
tor-like growth factor (HBEGF), Vav 3 onco-
gene (VAV3), E2F transcription factor 1
(E2F1), keratin 13 (KRT13), and interleukin-1
receptor, type II (IL1R2)] showing up- or
down-regulation of expression in some, but not
all, sets of arsenical-treated HUC-1 cells.
Figure 4A and B shows the transcriptional dif-
ferences between untreated HUC-1 cells and
arsenical-treated HUC-1 cells or MC-T2 cells
measured by Q-PCR assay. To examine the
correlation between gene expression changes
measured by microarray and by Q-PCR, we
analyzed 91 pairs of data for 13 genes in
HUC-1 cells exposed to the different concen-
trations of the three arsenicals and in MC-T2
cells. As shown in Figure 4C, in most cases,
gene expression levels measured by the two
methods showed a positive correlation, being
either up- or down-regulated in both cases
(quadrants I and III). Inconsistent results were
seen in quadrant II for VAV3 in 0.05 µM
MMAIII-exposed cells, KRT13 in 0.1 µM
MMAIII-exposed cells, E2F1 in 0.1 and 0.2 µM
MMAIII-exposed cells, and IL1R2 in 0.2 µM
DMAIII-exposed cells; and in quadrant IV
S100A8 in 0.5 µM DMAIII-exposed cells, IL8
in 0.2 µM DMAIII-exposed cells, and IL1R2
and IGFBP5 in MC-T2 cells.
The results of immunoblotting analysis
confirmed the changes in gene expression at
the protein level because protein levels of
CDH1, HBEGF, and KRT13 in arsenical-
treated cells and MC-T2 cells (Figure 5) agreed
well with the mRNA levels measured by
Q-PCR assay (Figure 4A). In addition, protein
expression of integrin β3 (ITGB3) (Figure 5)
was consistent with transcript levels deter-
mined by microarray.
Distinct gene alterations in HUC-1 cells
after long-term exposure to iAsIII, MMAIII, or
DMAIII. To determine which genes were
affected similarly by these three arsenicals and
which responded to specific arsenic com-
pounds, for further comparative analysis, we
selected those genes showing at least a 1.5-fold
higher or 2-fold lower expression in HUC-1
cells exposed to 0.5 µM iAsIII, 0.2 µM
MMAIII, or 0.5 µM DMAIII compared with
untreated HUC-1 cells.
Enhanced expression of 29, 9, and
28 genes was seen, respectively, in iAsIII-,
MMAIII-, and DMAIII-exposed cells (Table 2).
Of these, IL1R2 was the only gene showing
enhanced expression in response to all three
trivalent arsenic compounds (Figure 6A). Of
the genes showing enhanced expression in
iAsIII-, MMAIII-, or DMAIII-exposed cells, the
expression of 15 of 29 (51.7%), 4 of 9
(44.4%), and 18 of 28 (64.3%), respectively,
was enhanced uniquely by this one agent
(Figure 6A). A hierarchical dendrogram of all
51 genes affected by one or other of the arseni-
cals is shown in Figure 6B. Clearly, these three
trivalent arsenicals induced the expression of
distinct patterns of genes.
In addition, suppressed expression was seen
for 20, 19, and 29 genes in iAsIII-, MMAIII-,
and DMAIII-exposed cells, respectively
(Table 3). The number of genes uniquely
suppressed in iAsIII-, MMAIII-, or DMAIII-
exposed cells was 5 (25%), 6 (31.6%), and 14
(48.3%), respectively (Figure 6C). The higher
percentage of genes uniquely suppressed in
DMAIII-exposed cells shows that exposure to
DMAIII may confer a more diverse gene 
pattern than exposure to the other two arsenic
Su et al.
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Figure 4. Confirmation of the microarray results by Q-PCR analysis of gene transcripts: increased (A) or
decreased (B) levels both in HUC-1 cells exposed to arsenicals and in MC-T2 cells. Total RNA isolated
from iAsIII-, MMAIII-, or DMAIII-treated HUC-1 cells or MC-T2 cells was used in the Q-PCR assay as
described in “Materials and Methods.” Error bars represent the SD for triplicate samples from one experi-
ment. (C) Semilog scatterplot of gene expression levels measured by microarray (log2 of ratio) and Q-PCR
(ΔCt). y = 1.4089x + 0.6318; R2 = 0.6396.
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Figure 5. Western blot analysis of arsenical-treated
HUC-1 cells and MC-T2 cells. Cell extracts from
untreated passage-matched HUC-1 cells, arseni-
cal-treated HUC-1 cells, and MC-T2 cells were
separated by SDS–PAGE and immunoblotted with
the indicated antibodies as described in “Materials
and Methods.”
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Integrin β3
β-Actincompounds, consistent with the hierarchical
cluster analysis results (Figure 3B). However, in
contrast to the single gene showing enhanced
expression on exposure to all three agents,
11 genes showed suppressed expression on
exposure to all three agents (Figure 6C). Ten
are of known function [GJA1, ITGB3, collagen
type I alpha 1 (COL1A1), IGFBP5, MMP2,
myosin light polypeptide kinase (MYLK),
GATA binding protein 6 (GATA6), chemokine
(C-C motif) ligand 2 (CCL2), protein kinase C
alpha (PRKCA), and nucleoporin (NUP88)],
and one has unknown function. The hierarchi-
cal dendrogram for this set of 41 genes
(Figure 6D) showed that the genes suppressed
by each of these three trivalent arsenicals shared
greater similarity than the enhanced genes
(Figure 6B).
Repression of the IL1B-induced increase in
NF-κB activity in iAsIII-exposed HUC-1 cells.
Venn diagram analysis showed that IL1R2 was
the only gene to show enhanced expression
after exposure to the three test arsenicals. IL1R2
is one of the receptors of inﬂammatory cytokine
IL1; however, because of the lack of a cyto-
plasmic signaling domain, binding to IL1R2
attenuates IL1-mediated signal transduction,
such as the IL1B-induced increase in NF-κB
activation (Re et al. 1996). To investigate the
effect of overexpression of IL1R2 on NF-κB
signaling, we examined the transgenic
NF-κB–dependent promoter activity of arseni-
cal-exposed cells in response to IL1 stimulation.
As shown in Figure 7, in untreated HUC-1
cells, the activity of the NF-κB–dependent pro-
moter was increased by treatment with IL1B,
and the effect was dose-dependent, with
increases of 5.3-fold at 0.05 ng/mL and
8.6-fold at 0.2 ng/mL, then plateauing. In con-
trast, in cells exposed long-term to iAsIII, the
transgenic NF-κB activity showed only a slight
increase in response to IL1B. These results
demonstrate that the IL1-mediated NF-κB sig-
naling cascade was impaired in HUC-1 cells
exposed long term to iAsIII.
A methyltransferase inhibitor reactivates
arsenic-suppressed genes. Gene expression can
be inactivated through a wide spectrum of
mechanisms. To determine whether DNA
hypermethylation silencing was involved in
arsenic-induced gene suppression, we tested a
methyltransferase inhibitor, 5-aza-dC, for its
ability to restore IGFBP5 and MMP2 mRNA
levels (measured by semiquantitative RT-PCR
and Q-PCR) in HUC-1 cells treated with
arsenicals. As shown in Figure 8, chronic expo-
sure to 0.2 µM MMAIII signiﬁcantly reduced
the expression of IGFBP5 and MMP2 to 17.5
and 8.2% of control levels, respectively.
However, after 72 hr treatment with 0.5 or
2.0 µM 5-aza-dC, the expression of both genes
increased. Using 2 µM 5-aza-dC, IGFBP5, and
MMP2 gene expression increased 3.4- and
2.2-fold, respectively (Figure 8). These results
suggest that at least part of the MMAIII-
induced repression of genes is dependent on
DNA methylation.
Discussion
Toxicogenomics is a powerful tool for studying
the interaction between genes and environ-
mental stress in disease causation (Waters and
Fostel 2004). The results of a microarray-based
study performed to give a comprehensive idea
of the effects of trivalent arsenic compounds on
human urothelial cells showed that long-term
exposure of HUC-1 cells to nonlethal doses of
iAsIII, MMAIII, or DMAIII had distinct effects
on a variety of cellular responses. On the basis
of the morphology (Figure 2), the dendrogram
(Figure 3A), and the gene profile analyses
(Figure 6), the DMAIII-induced cellular and
molecular changes differed from those induced
by iAsIII or MMAIII. In addition, the gene
Profiles mediated by arsenite and methylated metabolites
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Table 2. Genes showing enhanced expression in HUC-1 cells exposed long-term to MMAIII, DMAIII, or iAsIII.
Cluster and gene name Gene symbol Function
MMAIII, DMAIII, and iAsIII
Interleukin-1 receptor, type II IL1R2 Interleukin-1, type II,
blocking receptor activity
MMAIII speciﬁc
Arachidonate 5-lipoxygenase-activating protein ALOX5AP Leukotriene biosynthesis
Thrombomodulin THBD Receptor activity
DMAIII speciﬁc
A kinase (PRKA) anchor protein 5 AKAP5 Signal transduction
Ataxin 1 ATXN1 RNA binding
CD22 antigen CD22 Cell adhesion
Connective tissue growth factor CTGF Regulation of cell growth, cell adhesion
RNA, U70 small nucleolar RNU70 Unknown
Integrin beta 1 binding protein 1 ITGB1BP1 Cell adhesion
E2F transcription factor 1 E2F1 G1 phase of mitotic cell cycle
Guanine nucleotide binding protein GNB2 signaling pathway
(G protein), beta polypeptide 2
Keratin 13 KRT13 Intermediate ﬁlament
Keratin 15 KRT15 Intermediate ﬁlament
Laminin, alpha 3 LAMA3 Cell surface receptor
Phosphoinositide-3-kinase, regulatory subunit, PIK3R1 Phosphatidylinositol 3-kinase activity
polypeptide 1
Protocadherin 1 PCDH1 Cell–cell signaling
Transducin (beta)-like 1X-linked receptor 1 TBL1XR1 Regulation of transcription
Vav 3 oncogene VAV3 Small GTPase-mediated signal 
transduction
V-myc myelocytomatosis viral oncogene homolog 1 MYCL1 Transcription factor activity
Xeroderma pigmentosum, complementation group A XPA Nucleotide-excision repair
iAsIII speciﬁc
E-cadherin CDH1 Cell–cell adhesion
CDC2-related protein kinase 7 CRK7 Protein kinase activity
Tubulin-speciﬁc chaperone d TBCD Beta-tubulin folding
Cisplatin resistance related protein CRR9p CRR9 Integral to membrane
Cyclin D2 CCND2 Regulation of cell cycle
Polymerase (DNA directed), beta POLB DNA replication
Ring ﬁnger protein 141 RNF141 Ubiquitin ligase complex
Nuclear factor of activated T-cells, NFATC2 Transcription factor activity
cytoplasmic, calcineurin-dependent 2
S100 calcium binding protein P S100P Calcium ion binding
Fem-1 homolog c (C. elegans) FEM1C Unknown
Transforming growth factor TGFB1I4 Transcription factor activity
beta 1 induced transcript 4
MMAIII and iAsIII
Diphtheria toxin receptor (heparin-binding HBEGF Growth factor activity
epidermal growth factor-like growth factor)
DMAIII and iAsIII
Glucose phosphate isomerase GPI Glucose-6-phosphate isomerase
activity, cytokine activity
Growth factor, augmenter of liver regeneration GFER Cell proliferation
Hect domain and RLD 6 HERC6 Ubiquitin cycle
Homeodomain interacting protein kinase 3 HIPK3 Protein kinase activity
Interleukin-8 IL8 Cytokine activity
Involucrin IVL Keratinocyte differentiation
SRY (sex determining region Y)-box 15 SOX15 Transcription factor activity
Mitogen-activated protein kinase kinase kinase 11 MAP3K11 JNK cascade
OC0717-S-0282a
S100 calcium binding protein A8 S100A8 Inﬂammatory response
Gene names and symbols are from UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). 
aClone ID of original subtraction libraries. expression pattern induced by iAsIII most
closely resembled that in tumorigenic MC-T2
cells. However, each of these three compounds
can cause DNA damage and cytogenetic altera-
tions in mammalian cells (Dopp et al. 2004;
Kligerman et al. 2003), inhibit nucleotide exci-
sion repair (Schwerdtle et al. 2003), and
induce morphologic transformation in Syrian
hamster embryo cells (Lee et al. 1985; Ochi
et al. 2004). The effects on cancer develop-
ment of the distinct changes in gene expression
caused by low-dose long-term exposure to
these three trivalent arsenic compounds require
further clariﬁcation.
It is important to note that the HUC-1
cells used in the present study were derived by
SV40 transformation (Christian et al. 1987).
The transforming ability of SV40 is mediated
by a large T-antigen oncoprotein binding to,
and inactivating, gatekeeper tumor suppressor
proteins, such as p53 and retinoblastoma (RB)
(Pipas and Levine 2001). p53 protein is a cru-
cial mediator of cellular responses to DNA
damage and can initiate a program of cell-cycle
arrest, cellular senescence, or apoptosis (Harris
and Levine 2005). In the absence of functional
p53 protein, cells lose genomic integrity and
are prone to cancer development. p53 func-
tions as a transcription factor up-regulating
many target genes, such as p21 (cyclin-depen-
dent kinase inhibitor 1A, Cip1), MDM2
(transformed 3T3 cell double minute 2), and
GADD45 (growth arrest and DNA-damage-
inducible, alpha) (Levine 1997). A recent
report (Liu et al. 2003) has shown that
myeloma cells lacking p53 are more sensitive
to arsenic trioxide (ATO), which induces
apoptosis and arrest of the cells in G2/M phase
of the cell cycle, whereas cells with wild-type
p53 are relatively resistant to ATO and are
arrested in G1 phase by ATO. Thus, cells con-
taining a wild-type or mutated/null p53 may
show different cellular responses to arsenicals.
Our findings showing transcriptional alter-
ations mediated by chronic exposure to arsenic
species in cells lacking functional p53 protein
might therefore differ from those seen in cells
with functional p53.
Our microarray proﬁling showed that sev-
eral of the genes responding to chronic expo-
sure to all three arsenicals were involved in the
regulation of signal transduction pathways. Of
the signiﬁcantly affected genes in the total of
2,000 tested, that coding for IL1R2 was the
only one to show enhanced expression after
long-term exposure to each of the three tri-
valent arsenicals. IL1R2 is a nonsignaling
decoy receptor of the strong proinﬂammatory
cytokine IL1. Binding of IL1 to IL1R2 attenu-
ates IL1-induced inﬂammatory responses, such
as NF-κB activation (Dower 2000; Wald et al.
2003). Our results (Figure 7) showed that the
increased IL1R2 expression caused by the tri-
valent arsenicals disrupted signal transduction
mediated by IL1B. Alterations of cellular signal
transduction are suggested to play crucial roles
in arsenic-mediated carcinogenesis (Qian et al.
2003). Arsenic has been shown to activate the
stress-induced kinase pathway of MAPK p38,
ERK (extracellular signal-regulated kinase),
and JNK (c-Jun N-terminal kinase) (Cavigelli
et al. 1996; Liu et al. 1996) and to repress the
STAT (signal transducers and activators of
transcription) signaling pathway (Hayashi
et al. 2002). It can also either stimulate or
inhibit NF-κB activation depending on the
concentration, exposure time, and cell type
(Harris and Shi 2003). For instance, arsenite or
ATO has been shown to induce apoptosis of
melanoma and lymphoma cells by inhibiting
NF-κB activity (Ivanov and Hei 2004; Mathas
et al. 2003); however, ATO enhances
CD95/Fas-induced apoptosis through NF-κB
activation (Woo et al. 2004). Further studies
are required to characterize the biologic signiﬁ-
cance of the overexpressed IL1R2 and suppres-
sion of NF-κB activity in urothelial cells
chronically exposed to arsenic.
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Figure 6. Analysis of altered gene expression in cells exposed to different trivalent arsenicals. (A, C) Venn
diagram analysis of overlapping sets of iAsIII-, MMAIII-, or DMAIII-enhanced (A) or -suppressed (C) genes.
Numbers in the overlapping regions represent genes modulated in the same direction by two or three
trivalent arsenicals. The number of genes modulated uniquely by a single arsenical is underlined.
Numbers in parentheses indicate the number of gene modulated after exposure to each arsenic com-
pound. (B, D) Hierarchical dendrogram analysis of the enhanced (B) and suppressed (D) genes.
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M 0.2 D 0.5 iAs 0.5Unexpectedly, the expression of genes that
are negatively associated with carcinogenesis
was also enhanced by arsenical exposure. For
instance, expression of CDH1, a major compo-
nent involved in cell–cell adhesion and fre-
quently negatively associated with metastatic
and invasive carcinomas (Thiery 2002), was
enhanced in iAsIII-exposed cells, and expression
of its precursor protein, protocadherin 1, was
enhanced in DMAIII-exposed cells. THBD is a
cell-surface–expressed glycoprotein playing a
role in anticoagulation (Van de Wouwer et al.
2004), and higher THBD expression in tumors
correlates with better survival and reduced
metastatic activity (Weiler and Isermann
2003). THBD expression was enhanced in
MMAIII- or iAsIII-exposed HUC-1 cells. The
present results suggest that a wide spectrum of
cellular responses are induced to cope with
chronic nonlethal toxic stresses.
In contrast to the single gene activated by
all three trivalent arsenicals, 11 genes were sup-
pressed by all three. Several of these are also
involved in signal transduction. For instance,
integrins, heterodimeric transmembrane recep-
tors composed of an α-chain and a β-chain, are
the major component of the focal adhesive
complex that regulates stress-ﬁber formation,
cell shape migration, and signal transduction
via molecules such as phosphatidylinositol
3-kinase and NF-κB (Filardo et al. 1995; Guo
and Giancotti 2004; Hood and Cheresh 2002).
A recent report has shown that sodium arsenite
reduces focal adhesions and the phosphoryla-
tion of focal adhesion kinase and paxillin
(Yancy et al. 2005), supporting the idea that
focal adhesions and the downstream signal
transduction pathways may be targets of
chronic arsenical exposure. GJA1 is a gap-
junction channel protein involved in cell com-
munication (Aasen et al. 2003). A recent study
has revealed the novel paradigm that GJA1 acts
as a positive regulator of the NF-κB signaling
cascade and that GJA1 not only is crucial in cell
communication but also plays a role in signal
transduction regulation (Matsuda et al. 2003).
MYLK is one of the cytoskeleton kinases
involved in focal adhesion and is also associated
with NF-κB activity induced by tumor necrosis
factor-α (Wadgaonkar et al. 2005). Taken
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Table 3. Genes suppressed in HUC-1 cells after long-term exposure to MMAIII, DMAIII, or iAsIII.
Cluster and gene name Gene symbol Function
MMAIII, DMAIII, and iAsIII
Chemokine (C-C motif) ligand 2 CCL2 Cell–cell signaling
Collagen, type I, alpha 1 COL1A1 Extracellular matrix
Connexin 43 GJA1 Cell–cell signaling
GATA binding protein 6 GATA6 Transcription factor activity
Insulin-like growth factor binding protein 5 IGFBP5 Regulation of cell growth
Integrin, beta 3 ITGB3 Cell–matrix adhesion
Matrix metalloproteinase 2 MMP2 Metallopeptidase activity
Myosin, light polypeptide kinase MYLK Protein kinase activity
Nucleoporin 88 kDa NUP88 Nuclear pore
Protein kinase C, alpha PRKCA Cell proliferation
Homo sapiens PAC clone RP5-1057M1 Unknown
from 7, complete sequence
MMAIII speciﬁc
A kinase (PRKA) anchor protein 5 AKAP5 Signal transduction
CDC-like kinase 3 CLK3 Protein kinase activity
OC0717-S-0282a
V-myc myelocytomatosis viral oncogene homolog 1 MYCL1 Transcription factor activity
DMAIII speciﬁc
CCAAT/enhancer binding protein (C/EBP), beta CEBPB Transcription factor activity
Cyclin A1 CCNA1 Regulation of cell cycle
Heparin-binding epidermal growth HBEGF Growth factor activity
factor-like growth factor
DNA-damage-inducible transcript 3 DDIT3 Cell cycle arrest
Fibroblast growth factor receptor 1 FGFR1 MAPKKK cascade, protein kinase activity
RNA pseudouridylate synthase domain containing 4 RPUSD4 RNA processing
Proteasome (prosome, macropain) subunit, PSMA3 Ubiquitin-dependent protein catabolism
alpha type, 3
Hypoxia-inducible factor 1, alpha subunit HIF1A Response to stress, signal transduction,
transcription factor activity
Chromosome 21 open reading frame 4 C21orf4 Unknown
N-Ethylmaleimide-sensitive factor NSF ATP-dependent peptidase activity
Ornithine decarboxylase 1 ODC1 Catalytic activity
Thioredoxin-like 5 TXNL5 Electron transporter activity
Thrombospondin 1 THBS1 Cell adhesion, signal transduction,
coagulation
iAsIII speciﬁc
3-Hydroxy-3-methylglutaryl-coenzyme A synthase 1 HMGCS1 Acetyl-CoA metabolism
Myristoylated alanine-rich protein kinase C substrate MARCKS Actin binding, cell motility
Nedd4 family interacting protein 2 NDFIP2 Signal transducer activity
Proteasome subunit, beta type, 1 PSMB1 Ubiquitin-dependent protein catabolism
Peroxisomal biogenesis factor 14 PEX14 Integral to peroxisomal membrane
MMAIII and iAsIII
Protease, serine, 11 (IGF binding) PRSS11 Serine-type endopeptidase activity,
regulation of cell cycle
DMAIII and iAsIII
Arachidonate 5-lipoxygenase-activating protein ALOX5AP Leukotriene biosynthesis
SMAD, mothers against DPP homolog 7 (Drosophila) SMAD7 Transforming growth factor beta receptor,
inhibitory cytoplasmic mediator activity
Transcription factor 12 TCF12 Regulation of transcription
Gene names and symbols are from UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). 
aClone ID of original subtraction libraries. 
Figure 7. Decreased IL1B-induced NF-κB activity
in chronic iAsIII-exposed HUC-1 cells. HUC-1 cells
exposed to 0.5 µM iAsIII for 25 passages and 
passage-matched untreated HUC-1 cells were
transfected with NF-κB reporter and control plas-
mids and then treated with 0, 0.05, 0.2, or 1.0 µg/mL
recombinant human IL1B. At the end of treatment,
ﬁreﬂy and Renilla luciferase activities were deter-
mined as described in “Materials and Methods.”
Triplicate samples were assayed in each experi-
ment. Data are the mean ± SD for three indepen-
dent experiments. 
Figure 8. Semi-quantitative analysis of transcript
levels in 5-aza-dC–treated cells. HUC-1 cells main-
tained in the presence of 0.2 µM MMAIII for 25 pas-
sages were left untreated or treated with 5-aza-dC
for 3 days as described in “Materials and
Methods,” and then RT-PCR  (gels) and Q-PCR (per-
centages) were used to analyze IGFBP5 and MMP2
mRNA levels in these cells and control cells.
*Mean of triplicate samples from one Q-PCR analysis.
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(%)*together, our results suggest that many signal
transduction cascades may be modulated by
chronic exposure to trivalent arsenicals.
Imbalanced expression of genes in response to
stress has been suggested to be involved in car-
cinogenesis (Hofseth 2004). The present study
revealed that arsenic induced toxicopathologic
injuries and that cellular adaptation to arsenic
was associated with alterations in the expression
of a complex of genes.
Generation of oxidative stress has been
proposed to be involved in the toxicity induced
by low-dose arsenic (Schoen et al. 2004). The
expression of many oxidative stress–responsive
genes is induced by arsenic exposure; examples
include superoxide dismutase 1 and NAD(P)H
quinone oxidoreductase, which respond to
oxidative stress generated by arsenic metabolic
methylation (Hamadeh et al. 2002); heme 
oxygenase 1, a marker for arsenic-induced
stress (Liu et al. 2001b); and glutathione
(Brambila et al. 2002), heat-shock protein
(Barnes et al. 2002), and multidrug-resistant
efﬂux transporters (Liu et al. 2001a), which are
induced during the acquisition of tolerance to
arsenic. These genes showed no major changes
in our gene profiles, although they were
included on the array. The differences in
expression proﬁles obtained in our system and
in others may be due to tissue-speciﬁc variation
but are more likely due to different dosages
and exposure times. In our system, we applied
iAsIII, MMAIII, and DMAIII at doses of 0.05 to
0.5 µM for more than 3 months (~ 25 pas-
sages), whereas the other studies mentioned
above involved the use of 0.05–25 µM iAsIII
for periods of only several hours to 2 weeks.
Our results therefore suggest that these oxida-
tive stress–related genes may be involved in the
carcinogenic process at a period earlier than the
window of this study.
Toxicant-induced gene expression changes
and cancer have been shown to be associated
with epigenetic modiﬁcations (Sutherland and
Costa 2003). Methylation of CpG islands
appears to be responsible for the transcrip-
tional silencing of critical genes in various
types of cancer (Egger et al. 2004; Jones and
Baylin 2002). Exposure of cells to arsenic
results in global or specific hypomethylation
(Chen et al. 2001b, 2004; Xie et al. 2004) or
hypermethylation of specific genes such as
tumor suppressor p53 (Mass and Wang
1997). Our microarray analysis showed that
the number of genes suppressed by all three
agents was much higher than the number
activated by all three, suggesting that down-
regulation of genes might be an effect com-
mon to all three of these trivalent arsenicals.
Furthermore, the methyltransferase inhibitor
5-aza-dC partially restored transcription of
IGFBP5 and MMP2, again implying that epi-
genetic gene regulation may be involved in
chronic arsenical–mediated gene modulation.
The various forms of arsenicals to which
humans are exposed complicate studies of the
mechanism of arsenic-mediated carcinogenesis.
In addition, the lack of appropriate animal
models and sensitive biomarkers for monitor-
ing the adverse effects of arsenic has also lim-
ited progress. However, recent investigations
have revealed that arsenic may exert its adverse
effects via epigenetic pathways. Because bio-
logic pathways are connected through a com-
plicated network, the ability to identify and
conﬁrm the roles of arsenic-induced differen-
tially expressed genes during cancer develop-
ment would help us understand how a normal
cell is transformed into a neoplasm and to
search for new intervention regimes. The char-
acterization of the gene expression profiles
induced by arsenicals may therefore provide an
understanding of their roles in carcinogenesis.
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